Page 2 - Cornelia Kutzer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: Marinomed Biotech AG / Key word(s): Agreement Marinomed's Australian Carragelose distribution network strengthened ...

DGAP-News: AFFiRiS AG / Key word(s): Study results AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology 27.05.2021 / 11:00 The issuer is solely responsible for the content of this announcem...

DGAP-News: AFFiRiS AG / Key word(s): Study results AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of

(0) DGAP-News: AFFiRiS AG / Key word(s): Conference/Study AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference 27.04.2021 / 09:00 Positive preclinical in vivo results with AFFiRiS' antibody mAB C6-17 to treat Huntington's disease to be presented at the 16 th Annual Huntington's Disease Therapeutics Conference - Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington's disease pathology - Human m...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s ... AFFiRiS AGApril 27, 2021 GMT Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathology Human mtHTT transgenic mice treated with mAB C6-17 showed significantly reduced mtHTT levels in peripheral organs and central nervous system and displayed improved motor performance Results set the ground for AFFiRiS’ potential first-in...